{
    "nct_id": "NCT00831506",
    "title": "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF-01913539) On The Safety, Tolerability, And Steady-State Pharmacokinetics Of Digoxin In Healthy Subjects",
    "status": "COMPLETED",
    "last_update_time": "2009-06-09",
    "description_brief": "This study has been designed to confirm, in healthy subjects, the lack of a clinically important pharmacokinetic interaction between Dimebon, at the proposed maximum commercial dose of 20 mg TID (administered every 8 hours), and digoxin (Lanoxin\u00ae) 0.125 mg QD, a sensitive P-gp substrate recommended by FDA.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "Dimebon (latrepirdine; PF-01913539)",
        "Digoxin (Lanoxin)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The protocol title and description state this is a Phase 1, randomized, double-blind, placebo-controlled, two-way crossover study in healthy subjects designed to evaluate the steady\u2011state effect of Dimebon (PF\u201101913539) on the safety, tolerability, and steady\u2011state pharmacokinetics of digoxin \u2014 i.e., a drug\u2013drug interaction (PK) study rather than an efficacy trial. \ue200cite\ue202turn0search2\ue202turn0search0\ue201",
        "Act: Dimebon (also known as latrepirdine, PF\u201101913539) is a small\u2011molecule drug that was developed for Alzheimer\u2019s disease with reported cognitive-enhancing / neuroprotective effects in early studies (subsequently failed in Phase 3). Because it is a small molecule developed to improve cognition in AD (not a biologic or a psychiatric\u2011symptom targeted agent), it best matches the \"cognitive enhancer\" category. References: clinical trial listing and published clinical reports and Pfizer press release on Dimebon development. \ue200cite\ue202turn0search8\ue202turn0search4\ue202turn0search1\ue201",
        "Reflect: Classification chosen = \"cognitive enhancer\" because (a) Dimebon/latrepirdine is a small\u2011molecule AD candidate developed for cognitive benefit, and (b) it is not a biologic nor primarily aimed at neuropsychiatric symptom management. Note important ambiguity: the specific study described is a PK drug\u2013drug interaction study in healthy volunteers (not an efficacy trial), so if the question focuses strictly on the current study's intent (non\u2011therapeutic PK assessment), one could also argue the trial itself is not testing cognitive or disease\u2011modifying effects and label it as 'N/A' for therapeutic target. I have therefore classified the drug's overall target category (cognitive enhancer) and documented the DDI study nature. Key sources: trial registry (NCT00831506 / Pfizer listing), PubMed clinical trial report, and Pfizer press release. \ue200cite\ue202turn0search2\ue202turn0search8\ue202turn0search4\ue201"
    ],
    "agent_type": "R) Multi-target",
    "explanation_agent": [
        "Reason: The described protocol is a Phase 1 drug\u2013drug interaction (PK) study of Dimebon (latrepirdine; PF-01913539) with digoxin rather than an efficacy trial, but the question asks to classify the drug's target type. Latrepirdine was originally a non-selective antihistamine repurposed for AD and has reported actions across multiple molecular systems (multireceptor activity, mitochondrial effects, modulation of NMDA/cholinergic signalling), so its mechanism is not a single, specific CADRO target. \ue200cite\ue202turn1search1\ue202turn0search2\ue201",
        "Act: Key facts extracted from public records \u2014 (1) the trial is registered as a Phase 1, randomized, double\u2011blind, placebo\u2011controlled, two\u2011way crossover study to evaluate Dimebon\u2019s effect on the steady\u2011state pharmacokinetics and safety of digoxin in healthy subjects (NCT00831506). \ue200cite\ue202turn1search0\ue202turn1search1\ue201 (2) Latrepirdine (Dimebon) is a small\u2011molecule compound with reported multi\u2011receptor and mitochondrial actions and unclear single mechanism; it was investigated as a cognitive enhancer for AD but failed in Phase 3. \ue200cite\ue202turn0search2\ue202turn0search3\ue201 (3) Digoxin is a cardiac glycoside acting on Na+/K+\u2011ATPase (included here only because the study is a PK DDI study). \ue200cite\ue202turn0search7\ue201",
        "Reflect: Given latrepirdine\u2019s heterogeneous reported pharmacology (antihistamine origin, weak cholinesterase and NMDA effects, mitochondrial/neuronal protection, etc.), no single CADRO category (e.g., purely Neurotransmitter Receptors D, or purely Metabolism/Bioenergetics J, or Synaptic Plasticity/Neuroprotection M) fully captures its actions. The most precise CADRO assignment is therefore R) Multi-target. I also note the important caveat that the specific clinical trial described is a non\u2011efficacy PK interaction study in healthy volunteers (i.e., not testing cognitive benefit in patients), but the CADRO classification requested applies to the drug\u2019s mechanistic target \u2014 hence the multi\u2011target assignment. \ue200cite\ue202turn0search1\ue202turn0search2\ue201",
        "Web search results used (key sources): 1) Trial registration / listing for the Dimebon\u2013digoxin PK study (NCT00831506). \ue200cite\ue202turn1search0\ue202turn1search1\ue201 2) Reviews summarizing latrepirdine (dimebon) mechanisms and its multi\u2011receptor / mitochondrial actions. \ue200cite\ue202turn0search2\ue202turn0search1\ue201 3) Pfizer/Medivation press release describing Phase 3 failure and program termination. \ue200cite\ue202turn0search3\ue202turn0search4\ue201 4) Standard pharmacology references on digoxin mechanism (Na+/K+\u2011ATPase inhibitor) referenced because the study assesses digoxin PK. \ue200cite\ue202turn0search7\ue202turn0search6\ue201"
    ]
}